Latest News

Damon R. Reed, MD, compared the carefully-considered off-label use of trastuzumab deruxtecan with a clinical trial experience in 2 rare sarcoma subtypes.

ASCO updates stage IV NSCLC guidance, adding repotrectinib and zongertinib, with trial-backed dosing and sequencing tips for ROS1 and HER2 tumors.

Phase 3 Asian trial shows acalabrutinib sharply improves progression-free survival vs chlorambucil-rituximab in untreated, medically unfit CLL patients with favorable safety.

Patients with advanced melanoma were treated with DOC1021, a dendritic cell vaccine.

Sara Hurvitz, MD, discusses VIKTORIA-1 data on gedatolisib in PIK3CA-mutant HR+/HER2- breast cancer, following the drug's recent FDA approval.

Patients favor subcutaneous pembrolizumab for faster visits and comparable safety, signaling a convenient new option across solid tumors.

Erika Hamilton, MD, discusses HER2CLIMB-05 data showing tucatinib plus HP maintenance extends PFS in HER2+ breast cancer, including brain metastases.

The FDA expanded the use of the radioligand therapy to the hormone-sensitive setting in metastatic prostate cancer.

During a live event, Midhun Malla, MD, and participants discussed toxicity considerations with third-line therapy selection for KRAS-mutant mCRC.

FDA orphan designation boosts enzomenib for ALL, as menin inhibitor trials show early responses and tolerable safety in relapsed leukemia.

NCCN now prefers gedatolisib plus fulvestrant, with or without palbociclib, for PIK3CA wild-type HR+/HER2– metastatic breast cancer after endocrine therapy.

The July 2026 oncology roundup spotlights rapid cancer drug approvals, new dosing options, a melanoma virus therapy vote, and key rejections shaping treatment trends.

FDA advisers back RP1 plus nivolumab for anti–PD-1–refractory advanced melanoma, citing durable responses despite design concerns and awaiting confirmatory IGNYTE-3 data.

The sBLA for subcutaneous amivantamab is supported by results from the phase 1b/2 OrigAMI-4 study.

FDA fast-tracks off-the-shelf CD19 CAR T cema-cel for MRD+ LBCL consolidation, as ALPHA3 data show strong MRD clearance with outpatient care.

A B7-H3–targeted antibody-drug conjugate showed benefit vs chemotherapy in relapsed osteosarcoma.

Digital app-based therapy helps breast cancer survivors cut anxiety over 12 months, while depression gains lag; coaching boosts early use.

WinPro trial shows adding micronized progesterone to pre-surgery letrozole fails to boost Ki67 suppression in ER+/PR+ breast cancer, but may ease hot flushes.

Phase 3 results show intravesical cretostimogene drives durable complete responses and bladder preservation in BCG-unresponsive NMIBC.

FDA fast-tracks ISM6331 for hard-to-treat pleural mesothelioma, spotlighting Hippo pathway targeting and early phase 1 results presented at ESMO 2026.

Real-world data show Enhertu drives strong responses in HER2-mutant NSCLC, including brain metastases, while highlighting ILD risks and dosing insights.

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee is to determine whether data from the IGNYTE trial can support an accelerated approval of RP1 plus nivolumab.

Adding emavusertib to ibrutinib boosts response rates in relapsed/refractory PCNSL, including in BTKi-experienced patients, while safety monitoring addresses prior FDA hold concerns.

SimpleScreen CRC has demonstrated a sensitivity of 81.1% for CRC detection.

In an interview, Brian C. Betts, MD, revealed how Roswell Park Comprehensive Cancer Center achieved a dramatic increase in patient survival after allogeneic hematopoietic cell transplant.

Monthly IVIG prophylaxis sharply lowers moderate infections in CLL with low IgG, suggesting better quality of life despite baseline Ig levels.

Study aims to lift pathological complete response above the roughly 5% seen with chemotherapy alone in resectable disease.

Sonesitatug vedotin boosted overall survival vs chemotherapy in second-line and later CLDN18.2-positive gastric/GEJ cancers.

FIT-001 updates show darlifarnib plus cabozantinib drives 33% to 50% responses and 13‑month PFS in pretreated patients with cabozantinib-naive ccRCC.

Dr Erica Stringer-Reasor of UAB discusses gedatolisib's FDA approval, its dual PI3K/mTOR mechanism, and what's next in HR+/HER2– breast cancer care.

Results of a retrospective study suggest that response to immune checkpoint inhibitors in sarcoma may be linked to other factors besides level of tumor mutational burden or mismatch repair deficiency.